In today’s briefing:
- China Resources Beverage IPO Trading – Still a Bit of Fizz Left
- CMCDI (133 HK): Concessions Don’t Go Far Enough
- CR Beverage (2460 HK) IPO: Trading Debut
- Laopu Gold (6181 HK): IPO Lock-Up Expiry Might Prove Golden for Global Index Inclusion
- The Heat Is On: News Flow and Sentiment in CHINA / HONG KONG (October 22)
- Conch Venture (586 HK): Interesting Angles, yet Undervalued
- CanSino Biologics (6185.HK/688185.CH) – Breakeven May Arrive Earlier than Expected
- Morning Views Asia: Adani Green Energy, CIFI Holdings, Medco Energi
China Resources Beverage IPO Trading – Still a Bit of Fizz Left
- China Resources Beverage (2460 HK) raised around US$750m in its Hong Kong IPO, after pricing at the top-end.
- China Resources Beverage manufactures and sells packaged drinking water and RTD soft beverages in China.
- We have looked at the company’s past performance and valuations in our previous notes. In this note, we will talk about the trading dynamics.
CMCDI (133 HK): Concessions Don’t Go Far Enough
- On the 27th September, China Merchants China Direct Investments (133 HK) (CMCDI) teased a share buyback and a special dividend. But as of today. no firm details have been forthcoming.
- CMCDI has also now offered to reduce management fees by 25 basis points in the new management agreement, which will be voted on by independent shareholders in November/December.
- This concession does not go far enough. Especially when 45% of the management fees are received by founder Victor Chu.
CR Beverage (2460 HK) IPO: Trading Debut
- China Resources Beverage (2460 HK) priced its IPO at HK$14.50 per share to raise the gross proceeds of US$649 million. The shares will start trading on 23 October.
- The IPO was discussed in CR Beverage IPO: The Bull Case, CR Beverage IPO: The Bear Case, CR Beverage IPO: The Investment Case, CR Beverage (2460 HK) IPO: Valuation Insights.
- The market sentiment of the peers has remained unchanged since the IPO launch. CR Beverage is fairly valued at the IPO price.
Laopu Gold (6181 HK): IPO Lock-Up Expiry Might Prove Golden for Global Index Inclusion
- Laopu Gold (6181 HK) is expected to fail the fcap threshold at the December 2024 review due to low free float unless its price surges ~22% in the next week.
- The 6-month lock-up expiry will lift the fcap closely above the threshold significantly increasing the probability of inclusion at the March 2025 review.
- If the mcap qualifies for the small-cap segment, its inclusion is possible at the November 2024 review due to lower fcap requirements.
The Heat Is On: News Flow and Sentiment in CHINA / HONG KONG (October 22)
- Hong Kong markets continue to outperform globally this year with short selling declining and mainland buying increasing. These trends should accelerate going into next year.
- Sun Art Retail (6808 HK)resumed trading after announcing that the company is entertaining one or more potential acquisition plans for the company. The company also announced strong 1H25 earnings.
- Shanghai Electric Group Company (2727 HK) announce a buyback plan for 10% of A and H shares outstanding. The company also announced the acquisition of the China Fanuc robotics business.
Conch Venture (586 HK): Interesting Angles, yet Undervalued
- China Conch Venture Holdings (586 HK) is sitting on a steep discount of 59% to its NAV. Its holding in Anhui Conch Cement (600585 CH) is already valued at HK$13.3/share.
- Its waste-to-energy business has a value of Rmb4.4bn by assuming 5x PER, but this business has a net book value of Rmb10bn. Pipeline capacity equals 21.7% of operational capacity.
- The new energy segment, including lithium battery recycling and the manufacture of positive and negative electrode materials, has solid prospects but is overlooked by the market.
CanSino Biologics (6185.HK/688185.CH) – Breakeven May Arrive Earlier than Expected
- CanSino’s performance picked up in 24Q2. CDMO revenue is a surprise, which would become the second growth curve. Effective cost control and increased demand for meningococcal vaccines narrowed net losses.
- The short-term highlight in business progress is PCV13i, whose approval process is faster-than-expected. This means CanSino’s revenue in 2025 may exceed expectations. Controlling shareholders and management have increased their holdings.
- CanSino’s revenue is expected to reach RMB750 million in 2024. If revenue this year reaches RMB800 million or above, it’s beyond expectations. Reasonable market value is at least RMB5-10 billion.
Morning Views Asia: Adani Green Energy, CIFI Holdings, Medco Energi
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.